CD52 (Approved for MS. Reduces accumulation of disability (≥1.0 point on EDSS) reduced by 66%, relapse rate by 72%, and by 55%. Reduces CCR3, CCR4, CCR5, CCR6, CXCR3, CXCL10, and CCL20. This evidence concerns the gene CCR4 and myeloid sarcoma.